Last $48.14 USD
Change Today +1.58 / 3.39%
Volume 562.4K
CPHD On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 5:20 PM 10/21/14 All times are local (Market data is delayed by at least 15 minutes).

cepheid inc (CPHD) Snapshot

Open
$46.86
Previous Close
$46.56
Day High
$48.33
Day Low
$46.37
52 Week High
03/13/14 - $55.89
52 Week Low
07/31/14 - $36.94
Market Cap
3.4B
Average Volume 10 Days
884.1K
EPS TTM
$-0.46
Shares Outstanding
70.2M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CEPHEID INC (CPHD)

cepheid inc (CPHD) Related Businessweek News

No Related Businessweek News Found

cepheid inc (CPHD) Details

Cepheid, a molecular diagnostics company, develops, manufactures, and markets integrated systems for testing in the clinical and non-clinical markets; and for application in legacy non-clinical market. Its systems enable molecular testing for organisms and genetic-based diseases by automating manual laboratory procedures. The company offers GeneXpert system that integrates sample preparation in addition to DNA amplification and detection; and SmartCycler system, which integrates DNA amplification and detection to allow rapid analysis of a sample. The GeneXpert system is designed for reference laboratories, hospital central laboratories, and satellite testing locations, such as emergency departments and intensive care units within hospitals, as well as physician offices and other alternate site laboratories. It also provides GeneXpert Infinity System for high volume testing. The company offers GeneXpert system for testing in the areas of healthcare associated infections, critical infectious disease, sexual health, women’s health, virology, oncology, and genetics. Cepheid sells its products through its direct sales force and distributors worldwide. It has collaboration agreements with FIND to develop a test that can detect mycobactrium tuberculosis and associated rifampin resistance from human sputum samples; and Life Technologies Corporation to develop reagents for use in the USPS BDS program. The company was incorporated in 1996 and is headquartered in Sunnyvale, California.

1,200 Employees
Last Reported Date: 02/27/14
Founded in 1996

cepheid inc (CPHD) Top Compensated Officers

Chairman, Chief Executive Officer and Member ...
Total Annual Compensation: $577.2K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $416.6K
President of Hbdc
Total Annual Compensation: $433.5K
Chief Medical & Technology Officer, Executive...
Total Annual Compensation: $448.1K
Chief Regulatory Officer and Executive Vice P...
Total Annual Compensation: $352.5K
Compensation as of Fiscal Year 2013.

cepheid inc (CPHD) Key Developments

Cepheid Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014; Provides Earnings Guidance for the Fourth Quarter and Fiscal Year Ending December 31, 2014

Cepheid reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company's total sales were $115,209,000 against $100,081,000 a year ago. Loss from operations was $3,396,000 against $834,000 a year ago. Loss before income taxes was $6,969,000 against $1,034,000 a year ago. Net loss was $26,381,000 or $0.38 basic and diluted per share against $7,648,000 or $0.11 basic and diluted per share a year ago. Non-GAAP measure of income from operations was $5,987,000 against $7,164,000 a year ago. Non-GAAP measure of net income was $4,653,000 or $0.06 diluted per share against $6,617,000 or $0.09 diluted per share a year ago. For the nine months, the company's total sales were $338,619,000 against $288,031,000 a year ago. Loss from operations was $15,282,000 against $6,105,000 a year ago. Loss before income taxes was $24,516,000 against $6,648,000 a year ago. Net loss was $7,235,000 or $0.10 basic and diluted per share against $1,381,000 or $0.02 basic and diluted per share a year ago. Net cash provided by operating activities was $4,843,000 against $11,748,000 a year ago. Capital expenditures were $37,323,000 against $31,005,000 a year ago. Non-GAAP measure of income from operations was $11,338,000 against $17,173,000 a year ago. Non-GAAP measure of net income was $6,386,000 or $0.09 diluted per share against $15,630,000 or $0.22 diluted per share a year ago. For the fiscal year ending December 31, 2014, the company expects total revenue in the range of $461 to $465 million; net loss in a range from $0.54 to $0.52 per share; and non-GAAP net income in the range of $0.11 to $0.13 per share. Expected non-GAAP net income excludes approximately $33 million related to stock-based compensation expense, approximately $9 million related to the amortization of debt discount and transaction costs, and approximately $4 million related to the amortization of acquired intangibles. The company continue to target full year non-GAAP gross margin of approximately 52% and non-GAAP commercial gross margin of approximately 62%. The company expects non-GAAP EPS of $0.11 to $0.13 and GAAP loss per share of $0.54 to $0.52. For the fourth quarter, the company expected total revenue in the range of $122 million to $126 million. The company expected non-GAAP gross margin of approximately 53%. The company expected non-GAAP EPS of $0.02 to $0.04 per share and GAAP loss per share of $0.17 to $0.15.

Cepheid to Report Q3, 2014 Results on Oct 16, 2014

Cepheid announced that they will report Q3, 2014 results at 2:00 PM, Pacific Standard Time on Oct 16, 2014

Cepheid, Q3 2014 Earnings Call, Oct 16, 2014

Cepheid, Q3 2014 Earnings Call, Oct 16, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CPHD:US $48.14 USD +1.58

CPHD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
GenMark Diagnostics Inc $9.02 USD +0.35
Luminex Corp $19.72 USD +0.25
Meridian Bioscience Inc $17.73 USD -0.04
Quidel Corp $27.14 USD -0.38
Sequenom Inc $3.27 USD -0.07
View Industry Companies
 

Industry Analysis

CPHD

Industry Average

Valuation CPHD Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 7.2x
Price/Book 9.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 6.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CEPHEID INC, please visit www.cepheid.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.